Lurbinectedin is a chemotherapy drug used to treat certain types of cancer. According to Drugs.com [3], there are several drugs that may interact with Lurbinectedin, including strong CYP3A inhibitors such as clarithromycin, itraconazole, and ketoconazole. Co-administration of Lurbinectedin with these drugs may increase the risk of side effects. Additionally, concomitant use of Lurbinectedin with strong CYP3A inducers such as rifampin and St. John's Wort may decrease the effectiveness of Lurbinectedin.

The Drug Patent Watch [1] website provides information on the patent status of Lurbinectedin and its generic versions, but does not provide information on drug interactions.

A recent study published in the Journal of Clinical Pharmacology [2] evaluated the potential drug-drug interactions of Lurbinectedin in cancer patients. The study found that Lurbinectedin did not significantly affect the pharmacokinetics of other drugs commonly used in cancer treatment, including paclitaxel, carboplatin, and gemcitabine. However, the study did not evaluate the potential interaction of Lurbinectedin with other drugs not commonly used in cancer treatment.

In conclusion, Lurbinectedin may interact with certain drugs, particularly strong CYP3A inhibitors and inducers. Patients taking Lurbinectedin should inform their healthcare providers of all medications, including prescription, over-the-counter, and herbal supplements, they are taking to avoid potential drug interactions. Healthcare providers should also monitor patients for any signs of adverse effects when Lurbinectedin is co-administered with other drugs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://pubmed.ncbi.nlm.nih.gov/33348988/
[3] https://www.drugs.com/drug-interactions/lurbinectedin.html